Citations

Clear

1526 citation(s) found for "Sun, Bo".

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Dulai, Parambir S. , Singh, Siddharth , Patel, Janki , Soni, Meera, Younossi, Zobair M. , Sebastiani, Giada , Ekstedt, Mattias , Hagström, Hannes , Stål, Per , Hultcrantz, Rolf, Loomba, Rohit , Prokop, Larry J. , Nasr, Patrik , Wong, Vincent Wai‐Sun , Kechagias, Stergios , Loomba, Rohit , Hagström, Hannes , Stål, Per

Mayo Clinic

Hepatology | January 28, 2017 | Volume: 65 | Issue: 5 | Pages: 1557-1565

10.1002/hep.29085 | PMID 28130788 Get It

Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD. Through a systematic review and meta‐analysis, we identified five adult NAFLD cohort studies reporting fibrosis stage–specific mortality (0‐4). Using fibrosis stage 0 as a reference population, fibrosis stage–specific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all‐cause and liver‐related mortality were estimated. The study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. Included were 1,495 NAFLD patients with 17,452 patient years of follow‐up. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all‐cause mortality, and this risk increased with increases in the stage of fibrosis: stage 1, MRR = 1.58 (95% CI 1.19‐2.11); stage 2, MRR = 2.52 (95% CI 1.85‐3.42); stage 3, MRR = 3.48 (95% CI 2.51‐4.83); and stage 4, MRR = 6.40 (95% CI 4.11‐9.95). The results were more pronounced as the risk of liver‐related mortality increased exponentially with each increase in the stage of fibrosis: stage 1, MRR = 1.41 (95% CI 0.17‐11.95); stage 2, MRR = 9.57 (95% CI 1.67‐54.93); stage 3, MRR = 16.69 (95% CI 2.92‐95.36); and stage 4, MRR = 42.30 (95% CI 3.51‐510.34). Limitations of the study include an inability to adjust for comorbid conditions or demographics known to impact fibrosis progression in NAFLD and the inclusion of patients with simple steatosis and nonalcoholic steatohepatitis without fibrosis in the reference comparison group. Conclusion: The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (H epatology 2017;65:1557‐1565).
Signalling pathways involved in hypoxia‐induced renal fibrosis
Liu, Minna , Ning, Xiaoxuan , Li, Rong , Yang, Zhen , Yang, Xiaoxia , Sun, Shiren , Qian, Qi

Mayo Clinic

Journal of Cellular and Molecular Medicine | January 18, 2017 | Volume: 21 | Issue: 7 | Pages: 1248-1259

10.1111/jcmm.13060 | PMID 28097825 Get It

Abstract Renal fibrosis is the common pathological hallmark of progressive chronic kidney disease ( CKD ) with diverse aetiologies. Recent researches have highlighted the critical role of hypoxia during the development of renal fibrosis as a final common pathway in end‐stage kidney disease ( ESKD ), which joints the scientist's attention recently to exploit the molecular mechanism underlying hypoxia‐induced renal fibrogenesis. The scaring formation is a multilayered cellular response and involves the regulation of multiple hypoxia‐inducible signalling pathways and complex interactive networks. Therefore, this review will focus on the signalling pathways involved in hypoxia‐induced pathogenesis of interstitial fibrosis, including pathways mediated by HIF , TGF ‐β, Notch, PKC / ERK , PI 3K/Akt, NF ‐κB, Ang II / ROS and micro RNA s. Roles of molecules such as IL ‐6, IL ‐18, KIM ‐1 and ADO are also reviewed. A comprehensive understanding of the roles that these hypoxia‐responsive signalling pathways and molecules play in the context of renal fibrosis will provide a foundation towards revealing the underlying mechanisms of progression of CKD and identifying novel therapeutic targets. In the future, promising new effective therapy against hypoxic effects may be successfully translated into the clinic to alleviate renal fibrosis and inhibit the progression of CKD .
Label-Free Neuroproteomics of the Hippocampal-Accumbal Circuit Reveals Deficits in Neurotransmitter and Neuropeptide Signaling in Mice Lacking Ethanol-Sensitive Adenosine Transporter
Oliveros, Alfredo , Starski, Phillip , Lindberg, Daniel M. , Choi, Sun, Heppelmann, Carrie J. , Dasari, Surendra , Choi, Doo‐Sup , Lindberg, Daniel, Choi, Doo-Sup

Mayo Clinic

Journal of Proteome Research | December 21, 2016 | Volume: 16 | Issue: 4 | Pages: 1445-1459

10.1021/acs.jproteome.6b00830 | PMID 27998058 Get It

Applications of integrative OMICs approaches to gene regulation studies
Wang, Panwen , Wang, Junwen , Qin, Jing , Yan, Bin , Hu, Yaohua , Wang, Junwen

Mayo Clinic

Quantitative Biology | November 19, 2016 | Volume: 4 | Issue: 4 | Pages: 283-301

10.1007/s40484-016-0085-y Get It

BackgroundFunctional genomics employs dozens of OMICs technologies to explore the functions of DNA, RNA and protein regulators in gene regulation processes. Despite each of these technologies being powerful tools on their own, like the parable of blind men and an elephant, any one single technology has a limited ability to depict the complex regulatory system. Integrative OMICS approaches have emerged and become an important area in biology and medicine. It provides a precise and effective way to study gene regulations.ResultsThis article reviews current popular OMICs technologies, OMICs data integration strategies, and bioinformatics tools used for multi‐dimensional data integration. We highlight the advantages of these methods, particularly in elucidating molecular basis of biological regulatory mechanisms.ConclusionsTo better understand the complexity of biological processes, we need powerful bioinformatics tools to integrate these OMICs data. Integrating multi‐dimensional OMICs data will generate novel insights into system‐level gene regulations and serves as a foundation for further hypothesis‐driven research.
A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands
Qin, Tai, Barron, Lindsey , Xia, Lu , Villarreal, Maria M., Zwaagstra, John C. , Collins, Cathy, Zwieb, Christian, Kodali, Ravindra, Hinck, Cynthia S. , Reddick, Robert L., O'Connor‐McCourt, Maureen D., Sun, Lu‐Zhe , Huang, Haojie , Yang, Junhua , Kim, Sun Kyung , Shu, Chang , Hinck, Andrew P.

Mayo Clinic

Oncotarget | November 15, 2016 | Volume: 7 | Issue: 52 | Pages: 86087-86102

10.18632/oncotarget.13343 | PMID 27863384 Get It

Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage
Fortune, Brett E. , García–Tsao, Guadalupe , Deng, Yanhong , Fallon, Michael B. , Sigal, Samuel H. , Chalasani, Naga , Lim, Joseph K. , Reuben, Adrian , Vargas, Hugo E. , Abrams, Gary A. , Lewis, Michele D. , Hassanein, Tarek , Trotter, James F. , Beavers, Kimberly L. , Ganger, Daniel , Thuluvath, Paul J. , Grace, Norman D., Groszmann, Roberto J., Ciarleglio, Maria , Sanyal, Arun J. , Vargas, Hugo E , Lewis, Michele D

Mayo Clinic

Journal of Clinical Gastroenterology | October 25, 2016 | Volume: 51 | Issue: 5 | Pages: 446-453

10.1097/mcg.0000000000000733 | PMID 27779613 Get It

Goals/Background: Data on acute variceal hemorrhage (AVH) in the United States is limited and the best method to stratify risk is not clear. Taking advantage of a prospective US cohort study, we aimed to (1) describe clinical outcomes of AVH and their predictors; (2) compare predictors of 6-week mortality. Study: Prospective 15-center US cohort of patients with cirrhosis presenting with endoscopically proven AVH, all of whom received antibiotics, vapreotide (a somatostain analog) infusion and endoscopic band ligation. Patients were enrolled between August 2006 and April 2008. Primary outcome was 6-week mortality. Secondary outcome was 5-day treatment failure. The prognostic value of Child-Turcotte-Pugh (CTP) class, Model for End-stage Liver Disease (MELD) score and a recent recalibrated MELD were compared. Results: Seventy eligible patient were enrolled; 18 (26%) patients died within 6-weeks of index bleed. Demographic, clinical, and laboratory data were compared between survivors and nonsurvivors. Multivariate models showed that admission CTP or the MELD score (separately) were independent predictors of survival. The discriminative values of CTP (area under receiver operating characteristic: 0.75) and MELD (area under receiver operating characteristic: 0.79) were good and not significantly different (P=0.27). However, calibration (correlation between observed and predicted mortality) test was significantly better for CTP than for MELD, with the recently described recalibrated MELD model having the worst agreement. Predicted mortality for CTP-A was <10%, CTP-B 10% to 30%; and CTP-C >33%. Conclusions: AVH mortality of 26% in the United States is in the upper range limit compared with recent series but may be due to inclusion of patients with more advanced cirrhosis. CTP score has the best overall performance in the prediction of 6-week mortality and is best at stratifying risk.
Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Detterbeck, Frank, Marx, Alexander , Roden, Anja C. , Marchevsky, Alberto M. , Mukai, Kiyoshi , Marino, Mirella , Bakker, Michael A. den , Yang, Woo‐Ick, Judge, Meagan , Hirschowitz, Lynn, Nicholson, Andrew G. , Chen, Gang

Mayo Clinic

Histopathology | October 14, 2016 | Volume: 70 | Issue: 4 | Pages: 522-538

10.1111/his.13099 | PMID 27735079 Get It

AimsThe International Collaboration on Cancer Reporting (ICCR) is a not‐for‐profit organization formed by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists–Association Canadienne des Pathologists in association with the Canadian Partnership Against Cancer, and the European Society of Pathology. Its goal is to produce standardized, internationally agreed, evidence‐based datasets for use throughout the world.Methods and resultsThis article describes the development of a cancer dataset by the multidisciplinary ICCR expert panel for the reporting of thymic epithelial tumours. The dataset includes ‘required’ (mandatory) and ‘recommended’ (non‐mandatory) elements, which are validated by a review of current evidence and supported by explanatory text. Seven required elements and 12 recommended elements were agreed by the international dataset authoring committee to represent the essential information for the reporting of thymic epithelial tumours.ConclusionsThe use of an internationally agreed, structured pathology dataset for reporting thymic tumours provides all of the necessary information for optimal patient management, facilitates consistent and accurate data collection, and provides valuable data for research and international benchmarking. The dataset also provides a valuable resource for those countries and institutions that are not in a position to develop their own datasets.
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
Rankin, Andrew, Erlich, Rachel, Fakih, Marwan , George, Thomas J. , Lee, Jeeyun , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Schrock, Alexa B. , Klempner, Samuel J. , Sun, James X. , Grothey, Axel , Ross, Jeffrey S , George, Thomas J , Fakih, Marwan

Mayo Clinic

The Oncologist | September 29, 2016 | Volume: 21 | Issue: 11 | Pages: 1306-1314

10.1634/theoncologist.2016-0148 | PMID 27682134 Get It

Abstract Introduction. A KRAS mutation represented the first genomic biomarker to predict lack of benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy in advanced colorectal cancer (CRC). Expanded RAS testing has further refined the treatment approach, but understanding of genomic alterations underlying primary and acquired resistance is limited and further study is needed. Materials and Methods. We prospectively analyzed 4,422 clinical samples from patients with advanced CRC, using hybrid-capture based comprehensive genomic profiling (CGP) at the request of the individual treating physicians. Comparison with prior molecular testing results, when available, was performed to assess concordance. Results. We identified a RAS/RAF pathway mutation or amplification in 62% of cases, including samples harboring KRAS mutations outside of the codon 12/13 hotspot region in 6.4% of cases. Among cases with KRAS non-codon 12/13 alterations for which prior test results were available, 79 of 90 (88%) were not identified by focused testing. Of 1,644 RAS/RAF wild-type cases analyzed by CGP, 31% harbored a genomic alteration (GA) associated with resistance to anti-EGFR therapy in advanced CRC including mutations in PIK3CA, PTEN, EGFR, and ERBB2. We also identified other targetable GA, including novel kinase fusions, receptor tyrosine kinase amplification, activating point mutations, as well as microsatellite instability. Conclusion. Extended genomic profiling reliably detects alterations associated with lack of benefit to anti-EGFR therapy in advanced CRC, while simultaneously identifying alterations potentially important in guiding treatment. The use of CGP during the course of clinical care allows for the refined selection of appropriate targeted therapies and clinical trials, increasing the chance of clinical benefit and avoiding therapeutic futility.
Left Internal Mammary Artery Versus Coronary Stents: Impact on Downstream Coronary Stenoses and Conduit Patency
Matsuzawa, Yasushi , Sara, Jaskanwal Deep Singh , Kwon, Taek‐Geun , Sun, Tao , Lennon, Ryan J. , Bell, Malcolm R. , Daly, Richard C. , Lerman, Lilach O. , Locker, Chaim, Guddeti, Raviteja R, Sara, Jaskanwal D. S., Lee, Seung-Jin, Zhang, Ming , Guddeti, Raviteja , Liu, Zhi Hui , Lee, Seung Jin , Schaff, Hartzell V. , Lerman, Amir

Mayo Clinic

Journal of the American Heart Association | September 25, 2016 | Volume: 5 | Issue: 9 | Pages: No page available

10.1161/jaha.116.003568 | PMID 27664803 Get It

Background The study compared downstream coronary and conduit disease progression in the left anterior descending coronary artery treated with coronary artery bypass grafting using the left internal mammary artery ( LIMA ) versus percutaneous coronary intervention with bare metal stent ( BMS ) or drug eluting stent ( DES ). Methods and Results A total of 12 301 consecutive patients underwent isolated primary coronary revascularization, of which 2386 met our inclusion criteria (Percutaneous coronary intervention, n=1450; coronary artery bypass grafting, n=936). Propensity score analysis matched 628 patients, of which 468 were treated to the left anterior descending with coronary artery bypass grafting with LIMA (n=314), percutaneous coronary intervention with BMS (n=94), and DES (n=60). Coronary angiograms were analyzed by quantitative coronary angiography ( QCA ; n=433). Cumulative downstream coronary and conduit disease progression were estimated by Kaplan–Meier method and effect of treatment type by Cox proportional hazard models. Patients treated with LIMA had significantly lower risk of downstream coronary disease progression at follow‐up angiogram compared with BMS and DES (hazard ratio [ HR ] [95% CI ], 0.34; [0.20–0.59]; P =0.0002; and HR [95% CI ], 0.39; [0.20–0.79]; P =0.01, respectively). LIMA was associated with a lower risk of conduit disease progression compared to BMS and DES ( HR [95% CI ], 0.18; [0.12–0.28]; P <0.001; and HR [95% CI ], 0.27; [0.16–0.46]; P <0.001, respectively). BMS was associated with higher HR for downstream coronary and conduit disease progression compared with DES , but the difference did not reach statistical significance ( HR [95% CI], 1.13; [0.57–2.36]; P =0.73; and HR [95% CI ], 1.46; [0.88–2.50]; P =0.14, respectively). Conclusions LIMA grafting to left anterior descending is associated with significantly lower risk of downstream coronary and conduit disease progression compared to percutaneous coronary intervention with BMS and DES .